Search Results

The VITEK 2 Gram Negative Moxifloxacin is designed for antimicrobial susceptibility testing of Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and Proteus mirabilis. It is intended for use with the VITEK 2 System as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.

The VITEK 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology. The bacterial isolate to be tested is diluted to a standardized concentration in 0.45% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 automatically fills, seals and places the card into the incubator/reader. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.

Here's an analysis of the provided text regarding the acceptance criteria and study for the VITEK® 2 Gram Negative Moxifloxacin device:

1. Table of Acceptance Criteria and Reported Device Performance

Notes:

• The document explicitly states the "FDA DRAFT document 'Guidance on Review Criteria for Assessment of Antimicrobial susceptibility Devices', dated March 8, 2000 and Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued Feb. 5, 2003" defined the criteria. However, the exact numerical thresholds for "acceptable performance" (e.g., minimum percentage for Essential Agreement) are not directly stated in this extract, only that 98.7% demonstrated acceptable performance. We infer from the statement that the 98.7% EA met the pre-defined acceptance criteria.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: Not explicitly stated as a total number. The study mentions "fresh and stock clinical isolates and stock challenge strains" and that an "external evaluation was conducted."
• Data Provenance: Not explicitly stated (e.g., country of origin, specific institutions). The phrasing "external evaluation" suggests data was collected outside of bioMérieux's internal labs. The data was a mix of "fresh and stock clinical isolates" (implying retrospective and potentially prospective clinical samples, or at least isolates derived from them) and "stock challenge strains" (likely standardized, well-characterized strains used for validation).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• This information is not provided in the given text.

4. Adjudication Method for the Test Set

• This information is not provided in the given text.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of Human Readers Improve With AI vs. Without AI Assistance

• No, this was not an MRMC study. The VITEK® 2 system is an automated device for antimicrobial susceptibility testing (AST), not an AI-assisted diagnostic imaging system where human readers interpret results. The comparison was between the automated device and a reference laboratory method (NCCLS agar dilution).

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Yes, this was a standalone study. The VITEK 2 device's performance was directly compared against the NCCLS reference method. The VITEK 2 system operates "automatically fills, seals and places the card into the incubator/reader" and "monitors the growth of each well... At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result." This describes an automated process without human interpretation as part of the primary device function being tested for performance.

7. The Type of Ground Truth Used

• Reference Method (NCCLS agar dilution method). The study explicitly states the VITEK 2 Gram Negative Moxifloxacin's performance was compared "with the NCCLS reference agar dilution method." This method is considered the gold standard for determining minimum inhibitory concentrations (MICs) of antimicrobials.

8. The Sample Size for the Training Set

• Not Applicable / Not Provided. The document describes a performance validation study against a reference method, not the development or training of a machine learning algorithm. While the device certainly has algorithms embedded, the text focuses on its clinical performance evaluation rather than its initial algorithmic training.

9. How the Ground Truth for the Training Set Was Established

• Not Applicable / Not Provided. As this was not an AI/ML training study in the typical sense of needing a "training set," this information is not relevant or stated in the provided text.

Ask a specific question about this device